Clinical characteristics of fulminant-type autoimmune hepatitis: An analysis of eleven cases

Y. Miyake, Yoshiaki Iwasaki, R. Terada, T. Onishi, R. Okamoto, N. Sakai, K. Sakaguchi, Y. Shiratori

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background: Although a few adult cases of fulminant-type autoimmune hepatitis have been reported, their clinical features and prognosis have remained uncertain. Aim: To assess the clinical features and prognosis of patients with fulminant-type autoimmune hepatitis. Methods: Eleven patients (10%) diagnosed with fulminant-type autoimmune hepatitis in accordance with the 1999 criteria of the International Autoimmune Hepatitis Group were analysed. Results: All 11 patients were female, with a median age of 53 years. Five patients survived without liver transplantation, one received a liver transplantation, and five died without liver transplantation. Nine patients (82%) survived for 2 weeks or more following diagnosis, without liver transplantation. Except for the patient receiving a liver transplantation, serum total bilirubin levels measured during the clinical course were significantly higher in non-survivors than in survivors, although the accompanying serum alanine aminotransferase levels measured for the two groups were similar. Most significantly, serum total bilirubin levels in non-survivors worsened during days 8-15, while levels in survivors improved during the same period. Conclusions: The short-term prognosis for patients with fulminant-type autoimmune hepatitis may be good. However, patients whose serum total bilirubin levels worsen during days 8-15 should be considered forq2 liver transplantation.

Original languageEnglish
Pages (from-to)1347-1353
Number of pages7
JournalAlimentary Pharmacology and Therapeutics
Volume23
Issue number9
DOIs
Publication statusPublished - May 2006

Fingerprint

Autoimmune Hepatitis
Liver Transplantation
Bilirubin
Serum
Survivors
Alanine Transaminase

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Clinical characteristics of fulminant-type autoimmune hepatitis : An analysis of eleven cases. / Miyake, Y.; Iwasaki, Yoshiaki; Terada, R.; Onishi, T.; Okamoto, R.; Sakai, N.; Sakaguchi, K.; Shiratori, Y.

In: Alimentary Pharmacology and Therapeutics, Vol. 23, No. 9, 05.2006, p. 1347-1353.

Research output: Contribution to journalArticle

Miyake, Y. ; Iwasaki, Yoshiaki ; Terada, R. ; Onishi, T. ; Okamoto, R. ; Sakai, N. ; Sakaguchi, K. ; Shiratori, Y. / Clinical characteristics of fulminant-type autoimmune hepatitis : An analysis of eleven cases. In: Alimentary Pharmacology and Therapeutics. 2006 ; Vol. 23, No. 9. pp. 1347-1353.
@article{d1632b53f9ec425daf7cac70f453ce2e,
title = "Clinical characteristics of fulminant-type autoimmune hepatitis: An analysis of eleven cases",
abstract = "Background: Although a few adult cases of fulminant-type autoimmune hepatitis have been reported, their clinical features and prognosis have remained uncertain. Aim: To assess the clinical features and prognosis of patients with fulminant-type autoimmune hepatitis. Methods: Eleven patients (10{\%}) diagnosed with fulminant-type autoimmune hepatitis in accordance with the 1999 criteria of the International Autoimmune Hepatitis Group were analysed. Results: All 11 patients were female, with a median age of 53 years. Five patients survived without liver transplantation, one received a liver transplantation, and five died without liver transplantation. Nine patients (82{\%}) survived for 2 weeks or more following diagnosis, without liver transplantation. Except for the patient receiving a liver transplantation, serum total bilirubin levels measured during the clinical course were significantly higher in non-survivors than in survivors, although the accompanying serum alanine aminotransferase levels measured for the two groups were similar. Most significantly, serum total bilirubin levels in non-survivors worsened during days 8-15, while levels in survivors improved during the same period. Conclusions: The short-term prognosis for patients with fulminant-type autoimmune hepatitis may be good. However, patients whose serum total bilirubin levels worsen during days 8-15 should be considered forq2 liver transplantation.",
author = "Y. Miyake and Yoshiaki Iwasaki and R. Terada and T. Onishi and R. Okamoto and N. Sakai and K. Sakaguchi and Y. Shiratori",
year = "2006",
month = "5",
doi = "10.1111/j.1365-2036.2006.02894.x",
language = "English",
volume = "23",
pages = "1347--1353",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Clinical characteristics of fulminant-type autoimmune hepatitis

T2 - An analysis of eleven cases

AU - Miyake, Y.

AU - Iwasaki, Yoshiaki

AU - Terada, R.

AU - Onishi, T.

AU - Okamoto, R.

AU - Sakai, N.

AU - Sakaguchi, K.

AU - Shiratori, Y.

PY - 2006/5

Y1 - 2006/5

N2 - Background: Although a few adult cases of fulminant-type autoimmune hepatitis have been reported, their clinical features and prognosis have remained uncertain. Aim: To assess the clinical features and prognosis of patients with fulminant-type autoimmune hepatitis. Methods: Eleven patients (10%) diagnosed with fulminant-type autoimmune hepatitis in accordance with the 1999 criteria of the International Autoimmune Hepatitis Group were analysed. Results: All 11 patients were female, with a median age of 53 years. Five patients survived without liver transplantation, one received a liver transplantation, and five died without liver transplantation. Nine patients (82%) survived for 2 weeks or more following diagnosis, without liver transplantation. Except for the patient receiving a liver transplantation, serum total bilirubin levels measured during the clinical course were significantly higher in non-survivors than in survivors, although the accompanying serum alanine aminotransferase levels measured for the two groups were similar. Most significantly, serum total bilirubin levels in non-survivors worsened during days 8-15, while levels in survivors improved during the same period. Conclusions: The short-term prognosis for patients with fulminant-type autoimmune hepatitis may be good. However, patients whose serum total bilirubin levels worsen during days 8-15 should be considered forq2 liver transplantation.

AB - Background: Although a few adult cases of fulminant-type autoimmune hepatitis have been reported, their clinical features and prognosis have remained uncertain. Aim: To assess the clinical features and prognosis of patients with fulminant-type autoimmune hepatitis. Methods: Eleven patients (10%) diagnosed with fulminant-type autoimmune hepatitis in accordance with the 1999 criteria of the International Autoimmune Hepatitis Group were analysed. Results: All 11 patients were female, with a median age of 53 years. Five patients survived without liver transplantation, one received a liver transplantation, and five died without liver transplantation. Nine patients (82%) survived for 2 weeks or more following diagnosis, without liver transplantation. Except for the patient receiving a liver transplantation, serum total bilirubin levels measured during the clinical course were significantly higher in non-survivors than in survivors, although the accompanying serum alanine aminotransferase levels measured for the two groups were similar. Most significantly, serum total bilirubin levels in non-survivors worsened during days 8-15, while levels in survivors improved during the same period. Conclusions: The short-term prognosis for patients with fulminant-type autoimmune hepatitis may be good. However, patients whose serum total bilirubin levels worsen during days 8-15 should be considered forq2 liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=33645703754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645703754&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2006.02894.x

DO - 10.1111/j.1365-2036.2006.02894.x

M3 - Article

C2 - 16629940

AN - SCOPUS:33645703754

VL - 23

SP - 1347

EP - 1353

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 9

ER -